Short Interest in Windtree Therapeutics, Inc. (NASDAQ:WINT) Expands By 30.2%

Windtree Therapeutics, Inc. (NASDAQ:WINT) was the target of a significant increase in short interest during the month of March. As of March 31st, there was short interest totalling 39,700 shares, an increase of 30.2% from the March 15th total of 30,500 shares. Currently, 0.5% of the shares of the stock are sold short. Based on an average trading volume of 249,600 shares, the days-to-cover ratio is currently 0.2 days.

Windtree Therapeutics Stock Up 14.8 %

WINT opened at $0.44 on Monday. The company has a market cap of $2.24 million, a P/E ratio of -0.02 and a beta of 0.61. The business’s 50-day moving average price is $0.37 and its 200-day moving average price is $0.68. The company has a current ratio of 2.40, a quick ratio of 2.40 and a debt-to-equity ratio of 2.00. Windtree Therapeutics has a 12 month low of $0.28 and a 12 month high of $18.48.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Renaissance Technologies LLC grew its stake in shares of Windtree Therapeutics by 8.8% in the first quarter. Renaissance Technologies LLC now owns 234,446 shares of the company’s stock worth $267,000 after purchasing an additional 18,946 shares during the last quarter. Millennium Management LLC grew its stake in shares of Windtree Therapeutics by 411.1% in the second quarter. Millennium Management LLC now owns 79,858 shares of the company’s stock worth $33,000 after purchasing an additional 64,232 shares during the last quarter. Envestnet Asset Management Inc. grew its stake in shares of Windtree Therapeutics by 894.7% in the third quarter. Envestnet Asset Management Inc. now owns 107,302 shares of the company’s stock worth $32,000 after purchasing an additional 96,515 shares during the last quarter. Citadel Advisors LLC bought a new stake in shares of Windtree Therapeutics in the second quarter worth about $27,000. Finally, Vanguard Group Inc. bought a new stake in shares of Windtree Therapeutics in the third quarter worth about $40,000. Hedge funds and other institutional investors own 29.33% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “neutral” rating on shares of Windtree Therapeutics in a research note on Wednesday, January 3rd.

Windtree Therapeutics Company Profile

Windtree Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead development programs include istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant, which is in Phase 2a clinical trial for the treatment of lung injury resulting from COVID-19; Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activator, which is in preclinical trial for the treatment of chronic and acute heart failure.